EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that trading in Q3 of the current financial year was materially higher than budget and at a run-rate in excess of market forecasts. As a result the Company is now confident of achieving revenues and adjusted EBITDA for 2016 which will exceed the high end of current market forecasts.
In addition, the Company announces that cash generation during the quarter has been strong and its net debt position has improved considerably. While the Company plans to continue investing during Q4 and early 2017 in capital expenditure to increase consumables capacity in Germany and to replace equipment in the USA, it now expects to be cash positive within the next 12 months.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
|EKF Diagnostics Holdings plc
Julian Baines, CEO
Richard Evans, Finance Director and COO
|00 44 29 2071 0570
|Panmure Gordon (UK) Limited
|00 44 20 7886 2500
Walbrook PR Limited
|00 44 20 7933 8780 or email@example.com
00 44 7980 541 893
00 44 7584 391 303